One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Appendectomy and Risk of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: A Nationwide Population-based Cohort Study
doi : 10.1093/ibd/izad141
Volume 30, Issue 6, June 2024
An Atlas Characterizing the Shared Genetic Architecture of Inflammatory Bowel Disease with Clinical and Behavioral Traits
doi : 10.1093/ibd/izad269
Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study
doi : 10.1093/ibd/izad125
Feasibility, Acceptability, and Preliminary Efficacy of Acceptance Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress
doi : 10.1093/ibd/izad122
HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients
doi : 10.1093/ibd/izad130
Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis
doi : 10.1093/ibd/izad123
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis
doi : 10.1093/ibd/izad142
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus
doi : 10.1093/ibd/izad143
Outcomes of a Comprehensive Specialist Inflammatory Bowel Disease Nursing Service
doi : 10.1093/ibd/izad145
Single Nucleotide Polymorphisms of the MEFV Gene E148Q Are Highly Associated With Disease Phenotype in Crohn’s Disease
doi : 10.1093/ibd/izad259
Differential Impact of Smoking on Methylome and Transcriptome in Crohn’s Disease and Ulcerative Colitis
doi : 10.1093/ibd/izad268
2ʹ-Hydroxycinnamaldehyde Alleviates Intestinal Inflammation by Attenuating Intestinal Mucosal Barrier Damage Via Directly Inhibiting STAT3
doi : 10.1093/ibd/izad283
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
doi : 10.1093/ibd/izad159
Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach
doi : 10.1093/ibd/izad229
Prognostic Value of Inflammatory Bowel Disease-associated Biomarkers in Patients With Immune Checkpoint Inhibitor Enterocolitis: A Retrospective Cohort Study
doi : 10.1093/ibd/izad121
Dietary Inflammatory Indices Are Not Associated With Inflammatory Bowel Disease Incidence and Progression
doi : 10.1093/ibd/izad249
Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States
doi : 10.1093/ibd/izae038
Correction to: Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
doi : 10.1093/ibd/izae096
Freeing Time and Reducing Costs: The Value of a Specialized Nursing Service in IBD
doi : 10.1093/ibd/izad201
Reply: “Targeted Probiotics Against Bacterial-Fungal Biofilms: A New Concept Seems to Bring Us Closer to Microbiome-Modulating Therapy for Inflammatory Bowel Disease�
doi : 10.1093/ibd/izad206
Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease
doi : 10.1093/ibd/izae048
Reply to: Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease
doi : 10.1093/ibd/izae049
The Association of Extra-oral Halitosis With Small Intestinal Bacterial Overgrowth in Inflammatory Bowel Disease
doi : 10.1093/ibd/izae056
